Instrument Inactif

Communiqués Arix Bioscience plc

Actions

ARIX

GB00BD045071

Gestion des placements et exploitants de fonds

Communiqués

25/04/23	Arix Bioscience : Notice of Annual General Meeting 2023	PU
25/04/23	Arix Bioscience : Proxy form for AGM 2023	PU
25/04/23	Arix Bioscience : Annual Report & Accounts to 31 December 2022	PU
13/08/21	Arix Bioscience : Interim Results for the Six Months Ended 30 June 2021	AQ
12/01/21	Arix Bioscience : Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer	PU
06/01/21	Arix Bioscience : Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)	PU
21/12/20	Arix Bioscience : Completion of sale of VelosBio	AQ
11/12/20	Arix Bioscience : Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)	PU
04/12/20	Arix Bioscience : Artios and Merck KGaA announce global strategic collaboration	AQ
10/11/20	Arix Bioscience : Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting	PU
04/11/20	Harpoon Therapeutics : Reports Third Quarter 2020 Financial Results and Provides Corporate Update	PU
19/10/20	Arix Bioscience : VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors	PU
07/09/20	Arix Bioscience : VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma	PU
13/08/20	Arix Bioscience Plc : - Notice of Results	PR
10/08/20	Arix Bioscience Plc : - LogicBio announces IND clearance for LB-001	PR
05/08/20	Pharmaxis: US$7 Million of US Bronchitol Launch Milestone Payment Brought Forward	PU
20/07/20	Arix Bioscience Plc : - Amplyx announces positive Phase 2 data	PR
10/07/20	Arix Bioscience : Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)	PU
10/07/20	Arix Bioscience Plc : - Atox Bio plans NDA submission for Q3 2020	PR
08/07/20	Arix Bioscience Plc : - VelosBio completes $137 million Series B financing	PR
01/07/20	Arix Bioscience Plc : - Director/PDMR Shareholding, Issue of Ordinary Shares	PR
12/06/20	Arix Bioscience Plc : - Aura presents updated AU-011 clinical data at ARVO 2020	PR
12/06/20	Arix Bioscience Plc : - Imara presents positive interim Phase 2a data at EHA	PR
12/06/20	Arix Bioscience Plc : - Autolus AUTO1 and AUTO3 data at EHA	PR
09/06/20	Arix Bioscience : to present at the Proactive One2One Biotech Forum	PU